Genpax is revolutionising infectious disease investigation with IDEM, our groundbreaking surveillance tool using whole genome sequencing analysis. IDEM uses precision genomics to uncover the true relationship between bacterial isolates, offering a comprehensive solution to strain identification and outbreak management. IDEM not only provides unrivalled accuracy and resolution to transmission events, but also provides healthcare professionals with markers of clinical significance, signalling the need for swift containment or patient review.
| Website | http://www.genpax.co |
| Revenue | $6.4 million |
| Employees | 22 (20 on RocketReach) |
| Founded | 2021 |
| Phone | +44 20 8123 0272 |
| Industry | Data Infrastructure and Analytics |
| Keywords | Bioinformatics Analysis, Whole Genome Sequencing, Healthcare Analytics, Microbial Genomics, Bacterial Identification, Next Generation Sequencing, Clinical Microbiology, Infection Control |
| Competitors | Tata Consultancy Services, Accenture, Cognizant Softvision, Infosys, Wipro, Capgemini, HCLTech, DXC Technology Morocco, IBM, EY +37 more (view full list) |
Looking for a particular Genpax employee's phone or email?
The Genpax annual revenue was $6.4 million in 2026.
Ray Schaaf is the COO and President of Genpax.
20 people are employed at Genpax.
Genpax is based in London, England.